6914-80-3

Basic information

• Product Name: Cyclopropanecarboxylic acid, 1-(aminocarbonyl)-, methyl ester
• CAS NO: 6914-80-3
• Molecular Formula: C6H9NO3
• Molecular Weight: 143.142
• Mol File: 6914-80-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Cyclopropanecarboxylic acid, 1-(aminocarbonyl)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopropanecarboxylic acid, 1-(aminocarbonyl)-, methyl ester(6914-80-3)
• EPA Substance Registry System: Cyclopropanecarboxylic acid, 1-(aminocarbonyl)-, methyl ester(6914-80-3)

Safety Data

• Hazardous Substances Data: 6914-80-3(Hazardous Substances Data)

Upstream product

• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 

Downstream Products

• 45434-02-4 (1-(aminomethyl)cyclopropyl)methanol 
• 68781-13-5 α-amino-cyclopropanecarboxylic acid hydrochloride 
• 153248-46-5 1-hydroxymethyl-1-(tert-butoxycarbonylaminomethyl)cyclopropane 
• 877204-21-2 (1-((1H-imidazol-1-yl)methyl)cyclopropyl)methanamine 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF THE ARYL HYDROCARBON RECEPTOR (AHR)

The present invention relates to bicyclic compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds. A-B-L-C (I)

NOVEL COMPOUND HAVING ABILITY TO INHIBIT 11B-HSD1 ENZYME OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof inhibiting 11β-HSD1 enzyme activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. Since the compound of the present invention selectively inhibits the activity of 11β-HSD1 (11β-Hydroxysteroid dehydrogenase type 1), the compound of the invention can be effectively used as a therapeutic agent for the treatment of diseases caused by the over-activation of 11β-HSD1 such as non-insulin dependent type II diabetes, insulin resistance, obesity, lipid disorder, metabolic syndrome, and other diseases or condition mediated by the excessive activity of glucocorticoid.

Process for the preparation of 1-aminocyclopropanecarboxylic acid hydrochloride

The present invention relates to a novel process for preparing 1-aminocyclopropanecarboxylic acid hydrochloride (ACC*HCl) of the formula STR1 ACC*HCl is prepared from a cyclopropane-1,1-dicarboxylic acid diester via an 1-aminocarbonylcyclopropanecarboxylic acid ester intermediate and an alkali metal salt or alkaline earth metal salt of 1-aminocarbonylcyclopropanecarboxylic acid. The process represents a simplification and gives improved product yields.